COVIDE-19. Other coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: COVID-19 Patients who have the clinical signs of COVIDE-19 infection such as fever, cough, sputum production, sore throat, and so on. Patients with the positive CT scan Patients who declare Informed Consent for this study.
Exclusion criteria
Exclusion criteria: Pregnant Women (based on WHO protocol) Lactating Women (based on WHO protocol) Individuals who exhibit specific allergic reactions to intravenous administration. Patients with/or with a history of dangerous underlying diseases such as IgA deficiency Patients with/or with a history of dangerous diseases such as cardiovascular and or hematological disorders (hemophilia, thalassemia, leukemia). Patients with/or with a history of underlying diseases such as liver and kidney disease Smokers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome: complete remission of clinical signs of disease. Timepoint: About one week after starting the treatment. Method of measurement: Clinical and laboratory questionnaire.;Negative result for COVID-19 RT-PCR test. Timepoint: About 7-14 days after starting the treatment. Method of measurement: Results of qRT-PCR test.;Normal CT Scan. Timepoint: About 7-14 days after starting the treatment. Method of measurement: Result of CT scan. | — |
Secondary
| Measure | Time frame |
|---|---|
| Recovery and normal levels of biomarkers associated COVID-19. Timepoint: At least 1 to 2 weeks after treatment. Method of measurement: Laboratory Techniques. | — |
Countries
Iran (Islamic Republic of)
Contacts
Ahvaz University of Medical Sciences